Author of

• 16489

  +

  P1.01 - Poster Session with Presenters Present (ID 453)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Epidemiology/Tobacco Control and Cessation/Prevention
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16506

    +

    P1.01-017 - The Dramatic Shift of Lung Cancer toward Young in Prisons (ID 5149)

    14:30 - 14:30  |  Author(s): E. Perrot
    • Abstract

    Background:
    Although prisoners could be at higher risk for lung cancers, very few studies focused on that particular population. In a previous cohort study (Carbonnaux et al. Oncology 2013;85:370–377), we found an early onset of lung cancer in imprisoned patients. The aim of the CARCAN study was to assess epidemiological characteristics, management, prognosis and incidence of lung cancer among prisoners compared to general population.
    
    Methods:
    We designed a multi-centric observational case-control study. Cases were lung cancer diagnosed in prison in 3 penitentiary medical units (PMU) of France from 2005 to 2013 (Lyon / Marseille / Toulouse). Up to 3 controls were selected for each case from hospital databases. Controls were randomly matched to cases for center, sex, and year of diagnosis. Overall and age-specific cumulated incidences were calculated in the penitentiary area covered by the 3 participating PMU and in the French population using national statistics.
    
    Results:
    Overall, 170 controls and 72 cases met the inclusion criteria and were analyzed. Cases were mainly men (99%). Mean age at diagnosis was 52.9 (±11.0) in prisoners and 64.3 (±10.1) in controls patients (P<10-4). Most of prisoners were current smokers compared to controls (83% vs 53%; P<10-4). We did not find significant difference in histologic type or TNM stage at diagnosis between the two groups. Also, there was no significant difference in first-line treatment type in both groups; especially there was no difference in the rate of patient undergoing supportive care only. Median time from first symptoms to first treatment was 3.3 months [2.7-3.9] in controls compared to 3.6 months [2.7-4.4] in prisoners (P=0.947). We found no significant difference in progression free and overall survival between the two groups. Cumulated incidence (2008-2013) in men was dramatically increased in prisons in each age category compared to the French incidence. Incidence was 4.5 fold higher in prisons than in the general population among 30-40 years old peoples; 3.4 fold higher in 40-50 yo and 1.4 fold higher in 50-60 and 60+ yo categories.
    
    Conclusion:
    There is a dramatic shift of lung cancer toward young peoples in prisons. However, presentation, management and prognosis are similar in prisoners compared to controls. These finding should justify a specific screening policy in that high-risk population.